Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 320 versus OPTIRAY 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 320 versus OPTIRAY 350.
OPTIRAY 320 vs OPTIRAY 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast during radiographic procedures.
Iodinated radiocontrast agent that attenuates X-rays and enhances visualization of vascular structures and organs during imaging procedures.
Intravenous administration: 50-150 mL of OPTIRAY 320 (ioversol 320 mg iodine/mL) per injection for contrast-enhanced CT; total dose not to exceed 250 mL. Intra-arterial: variable per procedure.
Intravenous administration: 50-150 mL of 350 mgI/mL solution for contrast-enhanced CT; dose determined by procedure, body weight, and clinical indication. Intra-arterial: Varies per procedure, typically 30-60 mL total. Maximum single dose not established; avoid exceeding 5 mL/kg body weight.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment; may exceed 20 hours in severe renal failure (CrCl <30 mL/min).
2.0 ± 0.4 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to 10-40 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours. Less than 1% excreted in feces via biliary route.
Renal: 90-95% as unchanged drug via glomerular filtration within 24 hours; biliary/fecal: <5%
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent